IN8bio Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
20
- Stock Symbol
-
INAB
- Share Price
-
$0.82
- (As of Friday Closing)
IN8bio General Information
Description
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Contact Information
Website
www.in8bio.comCorporate Office
- Empire State Building 350 5th Avenue
- Suite 5330
- New York, NY 10001
- United States
Corporate Office
- Empire State Building 350 5th Avenue
- Suite 5330
- New York, NY 10001
- United States
IN8bio Timeline
IN8bio Stock Performance
As of 13-Nov-2026, IN8bio’s stock price is $0.82. Its current market cap is $8.87M with 10.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.82 | $0.82 | $0.80 - $2.73 | $8.87M | 10.8M | 42.8K | -$1.00 |
IN8bio Financials Summary
As of 30-Sep-2026, IN8bio has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (2,667) | 15,110 | 20,114 | 52,080 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (17,846) | (17,293) | (27,890) | (27,368) |
| Net Income | (19,405) | (19,440) | (30,437) | (30,007) |
| Total Assets | 18,695 | 32,282 | 20,944 | 33,709 |
| Total Debt | 2,750 | 2,782 | 5,030 | 4,893 |
IN8bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
IN8bio Comparisons
Industry
Financing
Details
IN8bio Competitors (14)
One of IN8bio’s 14 competitors is Allogene Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Adicet Bio | Formerly VC-backed | Boston, MA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Century Therapeutics | Formerly VC-backed | Philadelphia, PA | ||||
| American Gene Technologies | Venture Capital-Backed | Rockville, MD |
IN8bio Patents
IN8bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026006719-A1 | Multifunctional molecules and methods of treatment | Pending | 28-Jun-2024 | ||
| EP-4820502-A1 | Methods of allogeneic hematopoietic stem cell transplantation and cancer treatment | Pending | 08-Dec-2023 | ||
| WO-2025122271-A1 | Methods of allogeneic hematopoietic stem cell transplantation and cancer treatment | Inactive | 08-Dec-2023 | ||
| WO-2025122271-A9 | Methods of allogeneic hematopoietic stem cell transplantation and cancer treatment | Inactive | 08-Dec-2023 | ||
| EP-4665362-A2 | Non-signaling chimeric antigen receptor gamma delta t-cells | Pending | 17-Feb-2023 | C07K16/2803 |
IN8bio Signals
IN8bio ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
IN8bio FAQs
-
When was IN8bio founded?
IN8bio was founded in 2016.
-
Where is IN8bio headquartered?
IN8bio is headquartered in New York, NY.
-
What is the size of IN8bio?
IN8bio has 20 total employees.
-
What industry is IN8bio in?
IN8bio’s primary industry is Biotechnology.
-
Is IN8bio a private or public company?
IN8bio is a Public company.
-
What is IN8bio’s stock symbol?
The ticker symbol for IN8bio is INAB.
-
What is the current stock price of IN8bio?
As of 13-Nov-2026 the stock price of IN8bio is $0.82.
-
What is the current market cap of IN8bio?
The current market capitalization of IN8bio is $8.87M.
-
Who are IN8bio’s competitors?
Allogene Therapeutics, Adicet Bio, Kite Pharma, Century Therapeutics, and American Gene Technologies are some of the 14 competitors of IN8bio.
-
What is IN8bio’s annual earnings per share (EPS)?
IN8bio’s EPS for 12 months was -$1.00.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process